Aurobindo Pharma was founded in 1986 by P.V. Ramprasad Reddy and K. Nithyananda Reddy to make semi-synthetic penicillins. It is headquartered in Hyderabad and today runs 29 manufacturing facilities with capacity for over 50 billion formulation units and 19,000+ MT of APIs. It sells in 150+ markets and, per the company, is the largest generic pharma company in the US by prescriptions dispensed and ranks among the top 10 generics players in eight European countries.

The group is organised around four commercial engines: US formulations (largest at 41% of Q1 FY27 revenue), European formulations (32%), Growth Markets (12%) and APIs (11.5%), with ARV (HIV) formulations making up the balance. Three subsidiaries carry the strategic weight: Eugia (injectables and specialty), Apitoria (APIs) and CuraTeQ (biosimilars and peptides).

Q1 FY27 revenue by business

The new growth stack

Management describes the business as moving from an investment phase to monetisation. The pieces: the Lannett acquisition (US$247M, closed after FTC approval, adds complex generics, controlled substances and US government channels; plant at about 40% utilisation), CuraTeQ biosimilars (denosumab filed with EMA, omalizumab EMA filing targeted Q3 FY27, 2 to 3 US filings guided within FY27), TheraNym (biologics CMO anchored by MSD, Unit 1 inaugurated June 2026, commercial revenue from 2028), the Pen-G plant at Kakinada (800 to 900 tonnes a month, backward integration into 6-APA and amoxicillin), a China OSD plant (annual target of 2 billion tablets) and the A1 Biochem CRO deal.

Source: company filings via Screener.in (consolidated). FY21 profit of ₹5,334 Cr included ₹3,195 Cr of one-time other income, which is why the 5-year profit CAGR shows only about 1%.

Last five quarters

Reading the numbers

Aurobindo has compounded revenue at about 11% over three years (6% over five), and profit at 23% over three years off the depressed FY23 base. Margins have held in a 20% to 21% band since FY24. The Q1 FY27 profit beat came from three places: revenue growth helped by rupee depreciation, gross margin up about 150 to 160 bps to 60.4% and a jump in other income to ₹224 Cr from about ₹117 Cr in the prior quarter. The EBITDA beat itself was modest (₹1,881 Cr against a Street estimate near ₹1,848 Cr in one poll), so part of the PAT upside is lower quality than the headline 25% suggests.

Two structural features deserve attention. Working capital is heavy: inventory days stand at 326 and the cash conversion cycle at 252 days, so growth absorbs cash. And return ratios are thin for a stock priced at 2.7x book: ROE is about 10% and ROCE about 13%, a product of a capex cycle (Pen-G, China, Eugia, TheraNym) that has yet to earn its cost of capital.

We project free cash flow to the firm for FY27 to FY36 using the Zumedha standard: WACC 12%, terminal growth 5%. FY27 is anchored to management guidance (double-digit growth, EBITDA above ₹8,000 Cr) and broker estimates; later years fade growth from 11.5% to 6%.

Sensitivity: value per share (₹) by WACC and terminal growth

No cell in this grid reaches the current price of ₹1,734. Run in reverse, the market price implies a discount rate of roughly 9.8% at 5% terminal growth, or 9.5% at 4.5%. That is a low hurdle for an Indian generics company with a 10% ROE and a regulatory-inspection risk profile, so the current price is discounting execution that is still to be delivered (biosimilars, Lannett synergies, Pen-G economics), not the business as it stands. A 12% WACC is deliberately conservative for a net-cash large-cap; we weight DCF at 30% for that reason.

Peer context (indicative, dates differ)

Peer multiples are compiled from public data pages with different as-of dates and should be treated as directional. Verify live before acting. Sector average P/E was cited near 37x in August 2026 but is skewed by Sun and Torrent.

Against its closest comparables (Dr. Reddy’s and Zydus, both near 19x to 20x), Aurobindo now trades at a clear premium on trailing earnings despite a lower ROE. On our reading of earlier broker research, the stock’s five-year average forward P/E is in the mid-teens, so the current 22.8x FY27E multiple is well above its own history. We apply 18x to 22x on FY27E EPS of ₹76.1 (midpoint 20x), which credits Aurobindo for the earnings upgrade cycle and biosimilar optionality but stops short of Sun-style multiples.

Book value is ₹652 per share (about ₹660 after Q1 profit, net of the US$85M buyback). Pharma franchises rarely trade near book, so we use book as a floor and a range of 1.8x to 2.2x FY27E book value of about ₹717 as the reference band, giving ₹1,290 to ₹1,580 with a midpoint of 2.0x at ₹1,435. The ROE-justified multiple is far lower: (ROE 11% minus growth 5%) divided by (cost of equity 12% minus 5%) is only about 0.9x. Because current returns do not support a premium to book on their own, NAV carries just 10% weight.

EPV values the business on sustainable current earnings with zero growth, so it works as a floor on what the existing franchise is worth.

At 11% to 13% WACC the EPV range is ₹586 to ₹692. Roughly 63% of today’s market cap therefore rests on growth the company has not yet delivered. That is normal for a reinvesting pharma business, but it shows how much of the price is a bet on the pipeline and integration. EPV carries 10% weight.

Aurobindo does not disclose segment EBITDA, so the split below is our estimate, constrained to management’s consolidated FY27 guidance (EBITDA above ₹8,000 Cr; Europe margin above 20%). Multiples reflect generic-pharma norms: US and Europe at a premium to APIs and ARV.

The option-value line is deliberately modest. TheraNym’s own target is US$150M to 200M of revenue by 2032 at 35% to 50% EBITDA margins, which we discount and probability-weight to about ₹2,000 Cr, and we add about ₹3,000 Cr for CuraTeQ’s biosimilar pipeline. Without any option value the SOTP is ₹1,412. Changing every segment multiple by one turn moves the answer by about ₹140 per share, giving a ₹1,358 to ₹1,640 band.

The five methods converge into a weighted fair value of ₹1,320 (DCF 30%, relative 25%, SOTP 25%, NAV 10%, EPV 10%).

Twelve-month price outcomes are built from FY28E EPS and an exit multiple. The base case uses Axis Securities’ EPS of ₹88.8 at 17x, a modest premium to Aurobindo’s own historical multiple; the bull case assumes the biosimilar and Lannett stories run ahead of plan.

The probability-weighted outcome is about ₹1,518, roughly 12% below the current price, and the upside in the bull case (+15%) is smaller than the downside in the bear case (-39%). A buy case therefore needs either a lower entry price (below ₹1,200) or evidence that FY28E EPS is heading for ₹100 or more, which would lift fair value toward ₹1,500.

Zones are set relative to the ₹1,320 blended fair value. At ₹1,734 the stock is 31% above it, inside the Exit band.

The estimates imply EPS growth of 26% in FY27 and 17% in FY28, which is the earnings case for the rally. Post-Q1, Axis lowered FY27E/FY28E PAT by 4.2%/6.4% while raising its target to ₹1,600 and cutting its rating to Hold on valuation, which is a useful cross-check on our own conclusion. Growth levers in order of visibility:

Our own DCF path is more conservative than a straight-line extrapolation of these estimates: revenue reaches about ₹54,300 Cr by FY31E (10% CAGR) and EBITDA margin settles at 22.5%. Upside to that path would come from biosimilars and biologics CMO reaching scale, which is exactly what the SOTP option value tries to capture.

Shareholding trend (%)

Top 10 institutional and fund house holders (approx. % of equity)

Promoter entity note: the largest single holder is the Penaka Family Trust at about 34.8%, alongside individual promoter-group members and group companies, which together make up the 51.88% promoter holding. Institutional figures are parent-AMC or entity-level (not scheme-wise), sourced from Simply Wall St and may lag the latest quarter. Refer to BSE/NSE shareholding filings for scheme-wise and FPI-wise detail.

Ownership has rotated in the past two quarters. Foreign holding bottomed at 13.95% in December 2025 and has since recovered to 16.38%, while domestic institutions have trimmed from a 27.66% peak to 25.05% as the stock rose (mutual funds alone slid from 19.5% to 16.7% between December 2025 and June 2026 per Axis). Promoter holding has been rock steady near 51.8%. The mix suggests domestic funds have been selling into strength while overseas money returns on the earnings upgrade, a pattern that often marks a late stage of a re-rating rather than the start.